Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00485966 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2008-11-05
Summary
This is a Phase 2, open-label, multicenter, efficacy, safety, and pharmacodynamic study of CX-3543 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).
Conditions
- B-Cell Chronic Lymphocytic Leukemia
Interventions
- DRUG
-
CX-3543
360 mg/m2 daily x 5 q 21 days
Sponsors & Collaborators
-
Cylene Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-06-30
- Completion
- 2008-06-30
Countries
- United States
Study Locations
More Related Trials
-
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
NCT03739554 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00481091 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
NCT01085656 ·Status: TERMINATED ·Phase: PHASE1
-
Hydroxychloroquine in Untreated B-CLL Patients
NCT00771056 ·Status: TERMINATED ·Phase: PHASE2
-
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
NCT00234481 ·Status: TERMINATED ·Phase: PHASE1
-
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
NCT00990587 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
NCT06708897 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04808570 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
NCT01456182 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
NCT02756611 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02966756 ·Status: RECRUITING ·Phase: PHASE2
-
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NCT06037018 ·Status: RECRUITING ·Phase: PHASE1
-
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
NCT01363297 ·Status: COMPLETED ·Phase: PHASE2
-
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
NCT01110031 ·Status: COMPLETED ·Phase: PHASE1
-
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02509546 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436 ·Status: RECRUITING ·Phase: PHASE2
-
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
NCT04668885 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
NCT00109356 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
NCT02238925 ·Status: COMPLETED ·Phase: PHASE2
-
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
NCT01419691 ·Status: COMPLETED ·Phase: PHASE2
-
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT03896269 ·Status: RECRUITING ·Phase: PHASE1
-
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02556346 ·Status: WITHDRAWN ·Phase: PHASE1